市場調查報告書
商品編碼
1372005
2030 年癲癇監測設備市場預測:按產品類型、技術、患者類型、配銷通路、最終用戶和地區進行的全球分析Epilepsy Monitoring Devices Market Forecasts to 2030 - Global Analysis By Product (Conventional Devices and Wearable Devices), Type, Technology, Patient Type, Distribution Channel, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球癲癇監測設備市場規模為 5.567 億美元,預計到 2030 年將達到 8.765 億美元,預測期內年複合成長率為 6.7%。
癲癇是一種以反覆發作為特徵的神經系統疾病,癲癇監測設備是醫學上用於識別、追蹤和管理癲癇狀況的設備和技術。這些工具對於癲癇的早期檢測和治療以及改善癲癇患者的生活品質至關重要。使用這種攜帶式腦電圖儀,可以在患者的日常生活中進行監測。它還涉及在大腦中植入電極以捕獲抗藥性癲癇患者的大腦活動。當非侵入性腦電圖 (EEG) 無法提供足夠的細節時,進行腦電圖 (EEG)。
根據世界衛生組織(WHO)2022年2月發布的最新資訊,全球約有5000萬人患有癲癇症,使其成為全球最常見的神經系統疾病之一。
隨著癲癇患者數量的增加,對癲癇監測設備的需求也增加。為了成功的疾病管理,不斷成長的患者群體需要額外的診斷和監測設備。此外,隨著患者數量的增加,最佳化治療的需求也隨之增加。監測設備可以幫助醫療保健專業人員為每個患者量身定做治療方法,以便採取最佳治療方法並提供適量的藥物,並幫助政府應對不斷上升的癲癇發病率。組織和醫療機構經常開展公共衛生活動。此類配合措施將提高監測和診斷服務的可及性並促進市場成長。
使用癲癇監測設備可能會因成本高昂而受到阻礙,特別是對於沒有足夠保險或財務資源的個人而言。因此,診斷和治療可能不充分或延遲。必須為監測設備支付高額費用的患者可能會遇到經濟困難。因此,您可能無法獲得所需的診斷或醫療護理。監測設備的高昂成本可能會完全阻礙其在貧窮國家等資源匱乏地區的採用,導致癲癇患者無法充分服務並阻礙市場成長。
即時資料分析、額外的監測通道和增強的訊號處理都是數位腦電圖系統的標誌。高密度腦電圖系統使用更多電極來記錄大腦活動。這些設備提供更精確的地理資料,可以幫助定位癲癇發作的來源並更準確地描述癲癇活動。監測設備(例如穿戴式腦電圖耳機)的小型化使得監測的侵入性降低且更易於使用。患者通常會發現這些設備佩戴起來更舒適且體積更小。這些進步帶來了更準確的診斷、更好的患者照護和更有效的癲癇管理。
醫療保健提供者可能不願意花錢購買需要強化培訓和持續技術援助的設備,這可能會限制高度複雜的監測設備的部署。醫護人員需要接受特殊訓練才能操作複雜的設備和分析資料,這需要時間並導致人員短缺。監測結果的準確性和可靠性可能會因人為錯誤而受到影響,而技術複雜性則更有可能導致人為錯誤,從而導致醫療機構推遲或避免實施複雜的監測解決方案。這是有可能的。
癲癇監測和診斷是受疫情影響的醫療保健服務之一。包括某些診斷測試在內的選擇性手術已被推遲或取消,以便為 COVID-19 患者騰出空間。這也影響了癲癇的檢測和治療方式。醫療保健負責人已開始使用遠端醫療服務(例如虛擬就診)來減少親自就診。遠端醫療使得遠距監測癲癇患者和改變治療策略成為可能。疫情期間,癲癇患者可能會延遲接受診斷和治療。一旦醫療服務恢復正常業務,患者可能會積壓,癲癇監測的需求也會增加。
由於其效率和安全性,傳統設備領域預計將出現良好的成長,預計市場將由傳統設備領域主導。 「常規設備」指使用腦電圖(EEG)持續監測患者的設備。傳統設備也常用於醫院和診所進行持續監測。專家可以使用常規技術準確診斷癲癇類型並提供最佳治療方案。這些因素可能與持續、非侵入性癲癇監測的需求不斷增加有關。市場上此類尖端產品的出現也支持了該領域的擴展。
由於深部腦部刺激(DBS)主要用於治療包括帕金森氏症和自發性震顫在內的運動障礙,因此預計深部腦部刺激領域在預測期內將具有最高的年複合成長率年成長率。 DBS 也正在被研究作為癲癇治療的一種選擇,特別是在其他治療方法失敗的抗藥性癲癇的情況下。儘管 DBS 不是典型的癲癇監測技術,但它確實有助於癲癇治療的整體情況。在考慮 DBS 作為癲癇治療方法之前,需要進行徹底的監測和評估。 EEG(腦電圖)監測和視訊腦電圖監測是兩種類型的癲癇監測工具,用於捕捉和檢查癲癇發作期間患者的大腦活動。
預計北美在預測期內將佔據最大的市場佔有率。美國癲癇監測設備擴張的主要要素是神經系統疾病(尤其是癲癇)的高患病以及大量的最終用戶。此外,癲癇患病的增加增加了對癲癇監測設備以有效治療患者的需求。此外,由於主要行業參與者的存在以及對產品開發和研究的大量投資,預計該領域的市場將迅速擴大。因此,由於上述方面,所研究的市場預計將在北美地區擴大。
由於患病上升、對神經系統疾病的認知不斷增強以及醫療技術的進步,預計亞太地區在預測期內將出現最高的年複合成長率。在醫療環境中使用癲癇監測設備進行長期視訊腦電圖監測。此外,還創建了幾種可以在家中使用的小工具,讓患者更容易監測自己的健康狀況。由於人們對癲癇及相關疾病的認知不斷提高以及醫療保健系統的發展,監測設備的使用越來越多。在醫療保健系統迅速擴張的國家尤其如此。
According to Stratistics MRC, the Global Epilepsy Monitoring Devices Market is accounted for $556.7 million in 2023 and is expected to reach $876.5 million by 2030 growing at a CAGR of 6.7% during the forecast period. Epilepsy is a neurological ailment marked by recurring seizures, and epilepsy monitoring devices are instruments and technology used in medicine to identify, track, and manage the condition. These tools are essential for the early detection and management of epilepsy, as well as for enhancing the quality of life for those who have the condition. With the help of this portable EEG gadget, patients may be monitored while going about their daily business. It aids in catching seizures that might not happen while you're in the hospital and it includes implanting electrodes into the brain to capture brain activity in people with drug-resistant epilepsy. When non-invasive EEG techniques don't yield enough details, it's employed.
According to the World Health Organization's February 2022 update, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.
The need for epilepsy monitoring equipment grows along with the number of people who have the condition. To successfully manage their illness, a growing patient population needs additional diagnostic and monitoring instruments. Moreover, the need for therapy optimization results from a growing patient population. In order to ensure that the best therapies are employed and that the correct quantities of pharmaceuticals are provided, monitoring devices assist healthcare providers in customizing treatment regimens to each patient and combat the rising frequency of epilepsy, governmental organizations and medical institutions frequently develop public health campaigns. These initiatives can concentrate on enhancing accessibility to monitoring and diagnosing services thus propel the market growth.
Access to epilepsy monitoring equipment may be hampered by high expenses, especially for individuals without sufficient insurance or financial resources. This may result in inadequate or delayed diagnosis and care. Patients who are required to pay a substantial amount of the cost of monitoring equipment could experience financial difficulties. This can deter individuals from getting the essential diagnostic procedures or medical care. The expensive expense of monitoring equipment may completely prohibit their adoption in areas with little resources, such as poor nations, leaving people with epilepsy underserved thus hamper the market growth.
Real-time data analysis, additional monitoring channels, and enhanced signal processing are all features of digital EEG systems. More electrodes are used in high-density EEG systems to record brain activity. These devices offer more precise geographical data, which is useful for locating the source of seizures and more accurately describing epileptic activity. Monitoring has become less obtrusive and more user-friendly because to the miniaturization of monitoring equipment, such as wearable EEG headsets. Patients typically find these gadgets to be more comfortable and less bulky to wear. Together, these developments lead to more precise diagnoses, better patient care, and more effective management of epilepsy.
The adoption of very complicated monitoring devices can be constrained because healthcare providers might be reluctant to spend money on equipment that needs intensive training and continuing technical assistance. To operate and analyze data from complicated equipment, healthcare personnel require specific training and result in lengthy training times and a staffing scarcity. The accuracy and dependability of monitoring findings may be jeopardized by human mistakes, which are made more likely by technical complexity and healthcare institutions may postpone or avoid deploying complicated monitoring solutions.
Epilepsy monitoring and diagnosis were among the healthcare services that were disrupted by the epidemic. In order to make room for COVID-19 patients, elective procedures including certain diagnostic tests were postponed or cancelled. This had an effect on how epilepsy was identified and treated. Healthcare practitioners started using telehealth services, such as virtual consultations, to reduce in-person visits. Telehealth made it possible to remotely monitor epilepsy patients and modify treatment strategies; often negating the need for physical monitoring equipment. During the pandemic, patients with epilepsy may have had delays in seeking a diagnosis or treatment. Once healthcare services resume regular operations, this might result in a backlog of patients and increased need for epilepsy monitoring.
The conventional devices segment is estimated to have a lucrative growth, due to its efficiency and safety, the market is projected to be dominated by the traditional devices segment. The term "conventional devices" refers to equipment used to continuously monitor patients using electroencephalograms (EEG). Conventional equipment is also commonly utilized in hospitals and clinics for on-going monitoring. Professionals can accurately diagnose the kind of seizure to provide the best course of therapy using conventional technology. These elements can be linked to the rising need for continuous, non-invasive epilepsy monitoring. The availability of such cutting-edge items on the market also aids in the segment's expansion.
The deep brain stimulation segment is anticipated to witness the highest CAGR growth during the forecast period, as deep brain stimulation (DBS) has been mainly employed to treat movement disorders including Parkinson's disease and essential tremor. It has also been investigated as a possible epileptic therapy option, particularly in situations of drug-resistant epilepsy where other therapies have failed. Although DBS is not a typical epilepsy monitoring technology, it does contribute to the overall picture of epilepsy therapy. A thorough monitoring and assessment are required before contemplating DBS as a therapy for epilepsy. EEG (electroencephalogram) and video-EEG monitoring are two types of epilepsy monitoring tools used to capture and examine a patient's brain activity during seizures.
North America is projected to hold the largest market share during the forecast period owing to the main drivers of the expansion of epilepsy monitoring devices in the United States are the high prevalence of neurological illnesses, particularly epilepsy, and the sheer volume of end users. Moreover, due to the rising prevalence of epilepsy, there is an increased need for epilepsy monitoring equipment in order to treat patients effectively. Additionally, it is anticipated that the market in this area would expand faster due to the presence of the key industry players there and their heavy investment in product development and research. The studied market is therefore anticipated to increase in the North American area as a result of the aforementioned aspects.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the rising epilepsy prevalence, rising awareness of neurological diseases, and improvements in medical technology. Long-term video-EEG monitoring with epilepsy monitoring equipment has been done in medical settings. Additionally, several gadgets were made to be used at home, making it easier for patients to keep an eye on their health. Monitoring devices were used as a result of rising epilepsy and associated condition awareness as well as the development of the healthcare system. This was especially true in nations with healthcare systems that were expanding quickly.
Some of the key players profiled in the Epilepsy Monitoring Devices Market include: Abbott Laboratories, Bioserenity, Boston Scientific Corporation, Brain Sentinel Inc., Cadwell industries, Compumedics USA inc, Emfit Corporation, Empatica Inc, Epilert, General Electric company, Kninklijke Philips N.V., Masimo, Medpage Ltd, Medtronic, Natus Medical Incorporated, Neurosoft, Neurowave systems, Nihon Kohden Corporation, Nonin and Pulse Guard International Ltd.
In September 2023, Abbott announced that it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.
In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain.
In August 2023, Cadwell Launches Sierra NMUS1 Ultrasound and Sierra 4 Software. The new Sierra NMUS1 offers high-resolution neuromuscular and musculoskeletal ultrasound, and needle guidance capabilities, with integrated controls.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.